The impact of pharmacoeconomics on the treatment of rheumatoid arthritis

Drug Benefit Trends

Volumn 14, Issue SUPPL. B, 2002, Pages 32-38

  Erkan, Doruk ^a   Yazici, Yusuf ^a   Harrison, Melanie J ^a   Paget, Stephen A ^a  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

Disease modifying antirheumatic drugs (DMARDs); Pharmacoeconomics; Rheumatoid arthritis

Indexed keywords

ACETYLSALICYLIC ACID; ANTIRHEUMATIC AGENT; AZATHIOPRINE; CORTICOSTEROID DERIVATIVE; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA ANTAGONIST; UNCLASSIFIED DRUG;

ADULT; ARTICLE; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG CHOICE; DRUG COST; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; PHYSICIAN; PRESCRIPTION; PRIMARY HEALTH CARE; REIMBURSEMENT; RHEUMATOID ARTHRITIS; SIDE EFFECT;

EID: 0036067352     PISSN: 10805826     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis: A prospective follow-up study of 147 patients
2. Arthritis therapies: Where are we now?
3. Physician treatment preferences in rheumatoid arthritis of differing disease severity and activity: The impact of cost on first-line therapy
4. The total costs of drug therapy for rheumatoid arthritis: A model based on costs of drug, monitoring, and toxicity